Skip to content
value.today
ADC Therapeutics SA logo

ADC Therapeutics SA

ADCT
$181 Mmarket cap on Oct 8, 2026+19.3% since Jan 2024
Compare
World rank
#16,612
Revenue
$81 M
For year ending December-2025
Net income
$-143 M
-175.3% margin
SEC filing
Employees
116
As on 2020
value.today research

ADC Therapeutics SA in brief

ADC Therapeutics SA is a listed company in the Biotechnology industry, based in Switzerland. Its market value was $181 M on 8 October 2026, which makes it the 16,612th largest listed company in the world and the 165th largest in Switzerland on this site. In the year to December 2025 it had sales of $81 M and a net loss of $143 M. It employs about 116 people and Ameet Mallik is its chief executive. Its largest product and service lines by sales in 2025 were License revenues and royalties (10%), License revenues (6%) and Royalties (3%). By market, the largest shares of its 2025 sales came from USA (90%) and EMEA (10%). Its shares trade under the symbol ADCT (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About ADC Therapeutics SA

ADC Therapeutics is a Clinical Stage Oncology Biotechnology company, development and commercialization of next generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. The headquarters is in Switzerland.

ADC Therapeutics company annual revenue was 209 million USD and annual net loss was -155 million USD as on Dec-2022.

ADC Therapeutics SA timeline

2 events, 2019–2020
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2020
  4. 🔔
    Initial public offering on NYSE
    Final prospectus filed with the SEC on 18 May 2020; shares registered for exchange trading on 11 May 2020.

Events of ADC Therapeutics SA from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$663 M$1.3 B$2.0 B$2.7 B202120222023202420252026

World rank over time

▼ down 11,836 places since 2021
2021-01-01: #4862#4,86220212022-01-07: #7370#7,37020222022-12-25: #16329#16,32920222023-07-30: #21503#21,50320232024-01-05: #19358#19,35820242026-03-08: #6954#6,95420262026-08-01: #16657#16,65720262026-10-08: #16698#16,6982026

Rank in Switzerland: #83 (Jan 2021) · #120 (Jan 2022) · #177 (Dec 2022) · #207 (Jul 2023) · #198 (Jan 2024) · #5 (Mar 2026) · #169 (Aug 2026) · #165 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
2.1×
Price / book
—
Free cash flow yield
-78.0%
Net margin (TTM)
-95.7%
Operating margin
-149.3%
Return on equity
—
Liabilities / assets
157.5%
Net debt
$-404M
Revenue growth
+14.9%
R&D / revenue
127.8%
Revenue per employee
$701 K
Profit per employee
$-1.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-123M$1MFY18Fiscal year ending Dec 2019: revenue $2M, net income $-116M$2MFY19Fiscal year ending Dec 2020: revenue —, net income $-246M—FY20Fiscal year ending Dec 2022: revenue $210M, net income $-157M$210MFY22Fiscal year ending Dec 2023: revenue $70M, net income $-240M$70MFY23Fiscal year ending Dec 2024: revenue $71M, net income $-158M$71MFY24Fiscal year ending Dec 2025: revenue $81M, net income $-143M$81MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$81M+14.9%$-122M$-143M-175.3%
Dec 2024$71M+1.8%$-131M$-158M-222.8%
Dec 2023$70M-66.9%$-166M$-240M-345.1%
Dec 2022$210M—$-123M$-157M-74.9%
Dec 2020——$-219M$-246M—
Dec 2019$2M+105.3%$-119M$-116M-4977.8%
Dec 2018$1M—$-126M$-123M-10798.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-141M$0M$-141M$-1.12—
Dec 2024$-124M$1M$-125M$-1.62—
Dec 2023$-119M$3M$-122M$-2.94—
Dec 2022$-138M$1M$-139M$-2.01—
Dec 2020$-169M$1M$-170M——
Dec 2019$-122M$0M$-122M——
Dec 2018$-121M$1M$-122M——

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$85M
Net income, trailing 12 months
$-81M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $17M, net income $-31M$17MDec ’24Three months to Mar 2025: revenue $23M, net income $-39M$23MMar ’25Three months to Jun 2025: revenue $19M, net income $-57M$19MJun ’25Three months to Sep 2025: revenue $16M, net income $-41M$16MSep ’25Three months to Dec 2025 (from the annual report): revenue $23M, net income $-6M$23MDec ’25Three months to Mar 2026: revenue $21M, net income $-33M$21MMar ’26Three months to Jun 2026: revenue $19M, net income $-17M$19MJun ’26Three months to Sep 2026: revenue $22M, net income $-25M$22MSep ’26

Latest quarter to Sep 2026: revenue $22M (+32.2% on a year earlier), net income $-25M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of ADC Therapeutics SA with the US Securities and Exchange Commission.

Annual results

Revenue
$81 M
Operating income
$-122 M
Net income
$-143 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$323 M
Total liabilities
$509 M
Total equity
$-186 M

As of December-2025

Top 100 institutional investors in ADC Therapeutics SA#

As of Sep 30, 2026
110 institutions held 82.0 M shares (about 64.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 48.6%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in ADC Therapeutics SA
#InstitutionShares heldChange (shares)% heldValueFiled
1Nantahala Capital Management, LLC12,576,184-12,076,184 (-48.99%)9.85%$15 MNov 13, 2026
2Redmile Group, LLC11,584,552+57,842 (+0.50%)9.07%$14 MNov 16, 2026
3TCG Crossover Management, LLC11,390,1750 (0.00%)8.92%$14 MNov 16, 2026
4BlackRock, Inc.7,179,305+159,212 (+2.27%)5.62%$9 MNov 13, 2026
5AIGH Capital Management LLC4,324,327New3.39%$5 MNov 2, 2026
6Opaleye Management Inc.4,070,819+3,370,819 (+481.55%)3.19%$5 MNov 16, 2026
7Goldman Sachs Group Inc3,485,435+1,571,011 (+82.06%)2.73%$4 MNov 16, 2026
8Morgan Stanley2,717,262-333,911 (-10.94%)2.13%$3 MNov 13, 2026
9Citadel Advisors LLC2,446,868+393,552 (+19.17%)1.92%$3 MNov 16, 2026
10AQR Capital Management LLC2,250,433+1,592,308 (+241.95%)1.76%$3 MNov 16, 2026
11State Street Corp1,702,853+17,017 (+1.01%)1.33%$2 MNov 12, 2026
12Two Sigma Investments, LP1,615,636+842,222 (+108.90%)1.27%$2 MNov 16, 2026
13D. E. Shaw & Co., Inc.1,514,496+795,176 (+110.55%)1.19%$2 MNov 16, 2026
14Geode Capital Management, LLC1,513,878+68,332 (+4.73%)1.19%$2 MNov 6, 2026
15Bank Of America Corp /de/1,289,144+938 (+0.07%)1.01%$2 MNov 16, 2026
16Vanguard Portfolio Management LLC1,082,160+185,068 (+20.63%)0.85%$1 MNov 13, 2026
17Acadian Asset Management LLC1,006,527+646,276 (+179.40%)0.79%$1 MNov 9, 2026
18UBS Group AG773,698+253,405 (+48.70%)0.61%$1 MNov 10, 2026
19Blue Owl Capital Holdings LP733,5680 (0.00%)0.57%$1 MNov 13, 2026
20Panagora Asset Management Inc695,401+122,585 (+21.40%)0.54%$1 MNov 12, 2026
21Jane Street Group, LLC641,221+579,954 (+946.60%)0.50%$1 MNov 12, 2026
22BNP Paribas Financial Markets632,568-20,281 (-3.11%)0.50%$1 MNov 12, 2026
23Northern Trust Corp593,895-130 (-0.02%)0.47%$1 MNov 16, 2026
24Platinum Investment Management LTD581,6090 (0.00%)0.46%$1 MNov 16, 2026
25Point72 Asset Management, L.P.447,786-3,201,358 (-87.73%)0.35%$1 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in ADC Therapeutics SA
#InstitutionShares heldChange (shares)% heldValueFiled
26Florida Trust Wealth Management Co400,000+169,565 (+73.58%)0.31%$0 MNov 5, 2026
27Prosight Management, LP399,900-7,424,849 (-94.89%)0.31%$0 MNov 13, 2026
28Renaissance Technologies LLC384,778New0.30%$0 MNov 12, 2026
29Jacobs Levy Equity Management, Inc263,997+122,653 (+86.78%)0.21%$0 MNov 16, 2026
30Charles Schwab Investment Management Inc258,687+34,629 (+15.46%)0.20%$0 MNov 16, 2026
31Bank of New York Mellon Corp252,005+360 (+0.14%)0.20%$0 MNov 5, 2026
32Commerce Bank235,849New0.18%$0 MNov 12, 2026
33XTX Topco Ltd226,937+86,596 (+61.70%)0.18%$0 MNov 16, 2026
34Russell Investments Group, Ltd.213,542-73,062 (-25.49%)0.17%$0 MNov 6, 2026
35Nuveen, LLC181,527+4,834 (+2.74%)0.14%$0 MNov 10, 2026
36FMR LLC179,171+46,396 (+34.94%)0.14%$0 MNov 10, 2026
37Barclays PLC162,765+68,501 (+72.67%)0.13%$0 MNov 6, 2026
38Shelton Capital Management130,724New0.10%$0 MNov 16, 2026
39Rhumbline Advisers120,941+3,577 (+3.05%)0.09%$0 MNov 10, 2026
40Alliancebernstein L.P.108,4700 (0.00%)0.09%$0 MNov 16, 2026
41Price T Rowe Associates Inc /MD/103,721+28,861 (+38.55%)0.08%$0 MNov 16, 2026
42Wilmington Savings Fund Society, FSB100,0000 (0.00%)0.08%$0 MOct 23, 2026
43Revolve Wealth Partners, LLC100,0000 (0.00%)0.08%$0 MOct 23, 2026
44Gsa Capital Partners LLP98,413+43,718 (+79.93%)0.08%$0 MNov 16, 2026
45Cantor Fitzgerald, L. P.95,648New0.07%$0 MNov 16, 2026
46Deutsche Bank AG\70,970-12,474 (-14.95%)0.06%$0 MNov 6, 2026
47Envestnet Asset Management Inc58,258New0.05%$0 MNov 16, 2026
48Jpmorgan Chase & Co57,659-94,881 (-62.20%)0.05%$0 MNov 12, 2026
49DAFNA Capital Management LLC57,081-20,000 (-25.95%)0.04%$0 MNov 16, 2026
50Invesco Ltd.56,352+590 (+1.06%)0.04%$0 MNov 12, 2026
51Vanguard Fiduciary Trust Co55,210-1,293 (-2.29%)0.04%$0 MNov 13, 2026
52HRT Financial LP53,037New0.04%$0 MNov 13, 2026
53MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.51,900+2,630 (+5.34%)0.04%$0 MNov 16, 2026
54Magnetar Financial LLC39,0920 (0.00%)0.03%$0 MNov 13, 2026
55Wells Fargo & Company/mn38,922-268,222 (-87.33%)0.03%$0 MNov 16, 2026
56Police & Firemen's Retirement System of New Jersey32,5440 (0.00%)0.03%$0 MNov 9, 2026
57DLK Investment Management, LLC30,467-2,688 (-8.11%)0.02%$0 MOct 9, 2026
58State of Alaska, Department of Revenue30,0000 (0.00%)0.02%$0 MOct 15, 2026
59Susquehanna International Group, LLP29,390New0.02%$0 MNov 16, 2026
60Vanguard Personalized Indexing Management, LLC26,948+9,941 (+58.45%)0.02%$0 MNov 16, 2026
61Cetera Investment Advisers26,623New0.02%$0 MNov 13, 2026
62Simplex Trading, LLC26,557+18,360 (+223.98%)0.02%$0 MNov 4, 2026
63R Squared Ltd24,402+10,476 (+75.23%)0.02%$0 MNov 6, 2026
64Saxony Capital Management, LLC23,7680 (0.00%)0.02%$0 MOct 15, 2026
65SEI Investments Co22,989-10,472 (-31.30%)0.02%$0 MNov 10, 2026
66Cerity Partners LLC20,441-6,703 (-24.69%)0.02%$0 MNov 13, 2026
67Lynx Capital Group LTD /adv20,000New0.02%$0 MNov 4, 2026
68Graham Capital Management, L.P.17,235New0.01%$0 MNov 16, 2026
69HSBC Holdings PLC16,660New0.01%$0 MNov 16, 2026
70Wealth Enhancement Advisory Services, LLC16,439-2,904 (-15.01%)0.01%$0 MOct 13, 2026
71Royal Bank Of Canada16,238+10,347 (+175.64%)0.01%$0 MNov 16, 2026
72Prudential Financial Inc14,2950 (0.00%)0.01%$0 MNov 16, 2026
73Two Sigma Securities, LLC13,578New0.01%$0 MNov 16, 2026
74ProShare Advisors LLC13,470-574 (-4.09%)0.01%$0 MOct 29, 2026
75Pallas Capital Advisors LLC12,412-189 (-1.50%)0.01%$0 MNov 12, 2026
76Simplicity Wealth,LLC11,391New0.01%$0 MOct 23, 2026
77Commonwealth Equity Services, LLC11,110-4,409 (-28.41%)0.01%$0 MNov 2, 2026
78CIBC Bancorp USA Inc.10,604New0.01%$0 MNov 13, 2026
79LPL Financial LLC10,565+400 (+3.94%)0.01%$0 MNov 6, 2026
80Perigon Wealth Management, LLC10,387-269 (-2.52%)0.01%$0 MOct 22, 2026
81Tower Research Capital LLC (TRC)10,368-7,993 (-43.53%)0.01%$0 MNov 16, 2026
82Aviso Wealth Management10,3430 (0.00%)0.01%$0 MNov 4, 2026
83Xponance LLC10,047New0.01%$0 MNov 3, 2026
84New York State Common Retirement Fund9,1000 (0.00%)0.01%$0 MNov 17, 2026
85Legal & General Group Plc9,0120 (0.00%)0.01%$0 MNov 16, 2026
86Ameritas Investment Partners, Inc.6,8590 (0.00%)0.01%$0 MNov 13, 2026
87Citigroup Inc6,825-42,847 (-86.26%)0.01%$0 MNov 4, 2026
88Optiver Holding B.V.3,977+1,271 (+46.97%)0.00%$0 MNov 16, 2026
89Jones Financial Companies Lllp3,0000 (0.00%)0.00%$0 MNov 13, 2026
90Sterling Capital Management LLC2,392+590 (+32.74%)0.00%$0 MOct 22, 2026
91GAMMA Investing LLC2,348+2,299 (+4691.84%)0.00%$0 MOct 8, 2026
92Nisa Investment Advisors, LLC2,020+1,650 (+445.95%)0.00%$0 MOct 20, 2026
93Caitong International Asset Management Co., Ltd1,912-5,136 (-72.87%)0.00%$0 MOct 29, 2026
94California State Teachers Retirement System1,4310 (0.00%)0.00%$0 MNov 13, 2026
95SJS Investment Consulting Inc.877+845 (+2640.62%)0.00%$0 MOct 26, 2026
96Arax Advisory Partners855-249 (-22.55%)0.00%$0 MNov 12, 2026
97Vanguard Global Advisers, LLC635New0.00%$0 MNov 13, 2026
98Osaic Holdings, Inc.509-3,500 (-87.30%)0.00%$0 MNov 12, 2026
99Rockefeller Capital Management L.P.4310 (0.00%)0.00%$0 MNov 13, 2026
100Allworth Financial LP391+287 (+275.96%)0.00%$0 MNov 17, 2026

All 110 institutional investors, with who bought and sold →

Mutual funds holding ADC Therapeutics SA#

64 funds hold shares worth $12 M (about 6.9% of the company). Since their previous reports 33 added shares and 18 sold, selling $20 M net.
Mutual funds holding ADC Therapeutics SA
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors2.74 M$3 M2.1%<0.01%+11%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.523,857$2 M0.41%0.01%+23%May 31, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.15 M$1 M0.90%<0.01%+15%Jul 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.316,782$1 M0.25%0.06%+0.1%May 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors742,327$1 M0.58%<0.01%newJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors668,942$1 M0.52%<0.01%−0.6%Jun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors360,391$0 M0.28%0.03%+40%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.95,226$0 M0.07%0.02%+21%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.258,687$0 M0.20%<0.01%+15%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors202,930$0 M0.16%<0.01%−76%Jun 30, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.177,078$0 M0.14%0.01%+58%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC173,365$0 M0.14%<0.01%no changeJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC152,716$0 M0.12%<0.01%+25%Jul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company42,246$0 M0.03%0.01%+20%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC116,021$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC111,381$0 M0.09%0.02%+59%Jun 30, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC30,255$0 M0.02%0.07%—Mar 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC104,376$0 M0.08%<0.01%no changeJun 30, 2026
🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc.79,373$0 M0.06%0.02%+389%Jun 30, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.78,102$0 M0.06%<0.01%+1.0%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation53,800$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC51,103$0 M0.04%<0.01%+16%Jul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC49,840$0 M0.04%<0.01%+202%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC49,840$0 M0.04%<0.01%+202%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors47,041$0 M0.04%<0.01%−0.8%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.43,766$0 M0.03%<0.01%−9.2%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.34,700$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC29,928$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.9,269$0 M<0.01%<0.01%+51%May 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC26,855$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION8,000$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC24,276$0 M0.02%0.01%+33%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC23,314$0 M0.02%<0.01%+94%Jul 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC21,617$0 M0.02%<0.01%+16%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC20,505$0 M0.02%<0.01%−74%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS20,514$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC19,177$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.18,596$0 M0.01%<0.01%+31%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.16,432$0 M0.01%<0.01%+41%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC4,808$0 M<0.01%<0.01%+29%May 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC13,186$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC13,438$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC3,799$0 M<0.01%<0.01%−28%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC3,759$0 M<0.01%<0.01%−29%May 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC11,857$0 M<0.01%<0.01%−84%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC11,430$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC3,124$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC10,003$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC2,526$0 M<0.01%<0.01%−5.3%May 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS8,122$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS7,557$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management6,859$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC6,990$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC6,000$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC5,372$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,524$0 M<0.01%<0.01%−74%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,966$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC2,876$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC2,691$0 M<0.01%<0.01%+23%Jun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.2,357$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC1,756$0 M<0.01%<0.01%−73%Jul 31, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC988$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC642$0 M<0.01%<0.01%+7.5%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.576$0 M<0.01%<0.01%+37%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 64 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at ADC Therapeutics SA#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$19.6 M
6 sales, 1 insider
Net, 12 months
-$19.6 M
open market only
Insiders on file
16
since
$2.2 M-$18.2 M$0May 2024: bought $0 (0 trades), sold $133 K (1 trades)May 24Jun 2024: bought $0 (0 trades), sold $28 K (7 trades)JunJul 2024: bought $2.2 M (2 trades), sold $0 (0 trades)JulDec 2024: bought $609 K (4 trades), sold $52 K (1 trades)DecMar 2026: bought $0 (0 trades), sold $1.4 M (2 trades)MarApr 2026: bought $0 (0 trades), sold $18.2 M (4 trades)Apr
Bought (open market)Sold (open market)Hover a month for the totals
ADC Therapeutics SA: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Ameet MallikChief Executive Officer, DirectorGrant or award+675,000——2.12 MForm 4
filed Peter J. GrahamChief Legal OfficerGrant or award+221,100——841,640Form 4
filed Mohamed ZakiChief Medical OfficerGrant or award+213,900——896,317Form 4
filed Jose CarmonaChief Financial OfficerGrant or award+203,700——938,076Form 4
filed Viviane MongesDirectorShares withheld for tax-2,596$3.080$8 K186,447Form 4
filed Peter HugDirectorShares withheld for tax-2,156$3.080$7 K263,344Form 4
filed Ron SquarerDirectorShares withheld for tax-15,196$3.080$47 K123,431Form 4
filed Timothy CoughlinDirectorShares withheld for tax-12,600$3.080$39 K72,400Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: ADC Therapeutics SA#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
6.4 M
5.1% of shares · 6.66 days to cover
Shares sold short, last 24 reportsAll stocks →

Index membership

  • : removed from S&P 500 (replaced by DFS)Discover Financial Services was listed on New York Stock Exchange.

Fails to deliver

  • : 524 shares at $1.42
  • : 10,900 shares at $1.06
  • : 7 shares at $1.11
  • : 5,985 shares at $1.32
  • : 27 shares at $1.24

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

ADC Therapeutics SA scorecard#

Passes 4 of the 18 checks that could be worked out: strongest in growth (2 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 8, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median2.1×Price to sales 2.1× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-78.0%Free cash flow is -78.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 5
    • ✓Revenue grew in the newest year14.8%Revenue up 14.8% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-27.1%-27.1% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-27.1%-27.1% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.12 vs -1.62Diluted EPS -1.12 in fiscal 2025 against -1.62 the year before (report's currency).
    • ✓Net income higher than five years earlier-$143 M-$143 M in fiscal 2025 against -$246 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$143 MNet income -$143 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-149.3%-149.3% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-149.3%-149.3% in fiscal 2025 against -58.8% in 2022.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities4.4×Current ratio 4.37 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-7.5×Operating income -7.5 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-6.99Z-score -6.99 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year30.8%Diluted shares up 30.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from ADC Therapeutics SA's statements, beside the median of Biotechnology.

ADC Therapeutics SA: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-149.3%-60.5%
Net margin-175.3%-68.9%
Revenue growth, 3 years a year-27.1%12.9%
Revenue growth14.9%15.8%
Free cash flow margin-173.8%-61.5%

5of 8on the Piotroski tests of financial strength

  • Net loss of $143 million, the 4th loss-making year in a row.
  • Free cash flow was negative: -$141 million.
  • The share count rose 30.8% in the year.
  • Shareholders' equity is negative: -$186 million.

ADC Therapeutics SA: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

ADC Therapeutics SA: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue8171702103402.31.1
Cost of revenue5.85.92.53.3r1.400—
Research and development104110127186r158142108118
Selling and marketing43445769652200
General and administrative37424874————
Total costs and expenses203201236333r296219122127
Operating income−121−131−166−123r−262−219−119−126
Interest and finance income8.812112.6r0.10.82.32.9
Interest expense and finance costs52504637r184.90.20
Share of profit of associates0−1.5−5.5−10————
Other non-operating income (expense)−20−25−29−23————
Income before tax−142−156−195−147r−252−246−116−123
Income tax1.00.2390.2r−210.30.60.2
Net income including minority interests———−156−230−246−116−123
Net income attributable to shareholders−143−158−240−157r−230−246−116−123
Earnings per share, basic-1.12-1.62-2.94-2.01————
Earnings per share, diluted-1.12-1.62-2.94-2.01————
Shares, weighted average (basic)12797827877654947
Shares, weighted average (diluted)127978278————
Balance sheet
Cash and cash equivalents261251279326467439116139
Receivables———73300——
Inventory4.22.3r1612r110——
Other current assets6.19.56.0r23r17117.1—
Current assets306291r336435r525450123—
Property, plant and equipment05.15.63.4r4.11.61.4—
Right-of-use (leased) assets1.38.4116.9r7.23.14.9—
Other intangible assets———1414108.4—
Investments in associates—01.67.6————
Non-current assets———83936315—
Total assets323322355491r618514138—
Accounts payable9.2181612125.33.3—
Debt due within a year3.00——6.63.60—
Current liabilities70806882r744020—
Long-term debt————87350—
Lease liabilities (non-current)1.08.0106.67.02.54.5r—
Non-current liabilities———3413781386.6—
Total liabilities509525503411r45217827—
Retained earnings−1,636−1,493−1,335−1,095r−925−695−449—
Shareholders' equity−186−203−14879154———
Total equity———89166336111126
Total liabilities and equity323322355491r618514138—
Shares outstanding126998281—775248
Cash-flow statement
Share-based compensation6.96.6134960381.10.5
Cash from operating activities−141−124−119−138r−233−169−122−121
Capital expenditure−0.3−0.9−3.2−0.7r−3.4−0.8−0.4−0.9
Intangible assets bought———−1.7−2.9−2.0−1.8−1.5
Cash from investing activities0.4−0.9−3.2−0.7r−6.7−2.8−2.2−2.5
Debt issued———0506300
Shares issued86610—043300
Shares bought back————00−0.10
Cash from financing activities1519774−0.9r267495101−0.0
Exchange-rate effect on cash0.3−0.10.2−0.20.00.20.1−0.1
Report10-K10-K10-K10-K20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What ADC Therapeutics SA sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product revenues, net(total)$74 M90%
  • License revenues and royalties$8 M9.6%
  • License revenues$5 M6.2%
  • Royalties$3 M3.5%

Business segments

  • Reportable$81 M100%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where ADC Therapeutics SA operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

ADC Therapeutics SA: countries of operation
CountryPresenceRevenue there
🇨🇭 SwitzerlandHeadquarters1 office—
🇬🇧 UK1 subsidiary—
🇺🇸 USA1 subsidiary$74 M90%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at ADC Therapeutics SA#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.5 M
Ameet Mallik
Other top executives, average
$1.4 M
the CEO earned 1.8× this
$100 invested is now
$92
ADC Therapeutics SA: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Ameet Mallik$2.5 M$6.0 M$1.4 M$92
2024Ameet Mallik$1.8 M$4.1 M$972 K$52
2023Ameet Mallik$3.8 M$2.7 M$2.8 M$43

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at ADC Therapeutics SA#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Directors and officers 1 · Material agreement 4 · Unregistered share sale 4 · Shareholder vote 4 · Results announced 15

ADC Therapeutics SA: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreementUnregistered share saleResults announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share saleResults announced8-K
Results announced8-K
RestructuringMaterial agreementUnregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Layoffs at ADC Therapeutics SA#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2025–2025
Latest
—
2025-06-11
ADC Therapeutics SA: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025············—
ADC Therapeutics SA: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How ADC Therapeutics SA compares in Biotechnology

  • Market cap$181 M · higher than 43% of 726
  • Revenue$81 M · higher than 67% of 647
  • Net margin-95.7% · higher than 42% of 408
  • Revenue growth14.8% · higher than 57% of 438
  • Price / sales2.1× · lower than 84% of 339
  • FCF yield-78.0% · higher than 14% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
ADC Therapeutics SA🇨🇭$181 M—-95.7%+14.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 8, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2020
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at ADC Therapeutics SA? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show ADC Therapeutics SA's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about ADC Therapeutics SA? Suggest a correction